Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

Rastogi, Shishir; Kumar, Ramesh; Sankineani, Sukesh Rao; Marimuthu, Kanniraj; Rijal, Laxman; Prakash, Shyam; Jalan, Divesh; Khan, Shah Alam; Sharma, Mehar Chand

doi:10.1007/s00264-012-1663-x

Cited by 24 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rastogi et al . () have demonstrated that serum VEGF levels might prove to be of diagnostic, predictive and prognostic value in patients with primary osteosarcoma. Additionally, Chen et al .…”

Section: Discussionmentioning

confidence: 99%

“…Osteosarcoma frequently tends to develop distant metastasis especially in lung and results in ultimate death. There is a plentiful of evidence to support significance of angiogenesis in the initiation, development and aggressiveness of osteosarcoma (Kaya et al 2000;Rastogi et al 2012;Chen et al 2012). VEGF is considered as a prime mediator for both physiological and pathological angiogenesis and has been implicated in carcinogenesis and metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High‐level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma

Shang

Wang

et al. 2016

Int J Experimental Path

View full text Add to dashboard Cite

Summary Periostin (PN), originally named as osteoblast‐specific factor‐2 (OSF‐2), has been involved in regulating adhesion and differentiation of osteoblasts. Recently many studies have shown that high‐level expression of PN is correlated significantly with tumour angiogenesis and prognosis in many kinds of human cancer. However, whether and how periostin expression influences prognosis in osteosarcoma remains unknown. This study aimed to examine the expression of PN in patients with osteosarcoma and explore the relationship of PN expression with clinicopathologic factors, tumour angiogenesis and prognosis. Immunohistochemistry was performed to determine the expression of PN in osteosarcoma and osteochondroma respectively. Vascular endothelial growth factor (VEGF) and CD34 were also examined in tissues from the osteosarcoma patients mentioned above. The results showed that PN expression was significantly (P < 0.05) higher in osteosarcoma (80.9%) than in osteochondroma (14.7%). Increased PN protein expression was associated with histological subtype (P = 0.000), Enneking stage (P = 0.027) and tumour size (P = 0.009). The result also showed that high expression of PN correlated with VEGF expression (r = 0.285; P = 0.019) and that tumours with PN‐positive expression significantly had higher microvessal density (44.6 ± 13.7 vs. 20.6 ± 6.5; P = 0.000) compared to those in normal bone tissues. Additionally, the expression of PN was found to be an independent prognostic factor in osteosarcoma patients. In conclusion, our findings suggest that PN may have an important role in tumour progression and may be used as a prognostic biomarker for patients with osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

High‐level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma

Shang

Wang

et al. 2016

Int J Experimental Path

View full text Add to dashboard Cite

show abstract

“…For the purposes of this article, the abbreviation VEGF refers to isoform VEGF-A unless otherwise indicated. Serum VEGF levels are elevated in many patients with cancer, including those with osteosarcoma (6)(7)(8). Inhibition of VEGF effectively suppresses osteosarcoma-induced angiogenesis in a murine model of osteosarcoma (9).…”

Section: Introductionmentioning

confidence: 99%

Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma

Ohba

Cates

Cole³

et al. 2014

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…Significantly higher levels of VEGF were observed in bone sarcoma patients compared to healthy controls in three articles [23–25], whereas no significant difference was reported in the two others [21, 22]. However, each of these studies included less than 50 osteosarcoma patients.…”

Section: Discussionmentioning

confidence: 96%

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

et al. 2017

View full text Add to dashboard Cite

BackgroundAngiogenesis is essential for the progression and metastatic spread of solid tumours. Expression of vascular endothelial growth factor (VEGF) has been linked to poor survival among osteosarcoma patients but the clinical relevance of monitoring blood and urine angiogenic factors is uncertain. The aim of this study was to determine the prognostic significance of blood VEGF and blood and urinary basic fibroblast growth factor (bFGF) levels in osteosarcoma patients, both at diagnosis and during treatment.MethodsPatients with localised or metastatic osteosarcoma enrolled in OS2005 and OS2006 studies between 2005 and 2011 were prospectively included in this study. VEGF and bFGF levels in serum and plasma and bFGF levels in urine were measured by ELISA at diagnosis, before surgery, and at the end of treatment. Endpoints considered for the prognostic analysis were histological response, progression-free and overall survival. Kruskal-Wallis tests were used to compare the distribution of baseline biomarker values across the different subgroups, and paired sample Wilcoxon rank tests were used to analyze changes over time. Association between biomarker levels and outcomes were assessed in multivariable models (logistic regression for histologic response, and Cox models for survival).ResultsSamples were available at diagnosis for 269 patients (54% males; age ≤ 18 years: 73%; localised disease in 68%, doubtful lung lesions in 17%, and metastases in 15%). High serum VEGF and bFGF levels were observed in respectively 61% and 51% of patients. Serum and plasma VEGF values were not strongly correlated with one another (r = 0.53). High serum and plasma VEGF levels were significantly more frequent in patients with large tumours (≥10 cm; p = 0.003 and p = 0.02, respectively). VEGF levels fell significantly during pre-operative chemotherapy (p < 0.0001). No significant correlation was found between this variation and either the histological response, progression-free survival or overall survival (p = 0.26, p = 0.67, and p = 0.87, respectively). No significant association was found between blood or urinary bFGF levels and clinical characteristics, histological response, or survival.ConclusionsLevels of VEGF and bFGF angiogenic factors are high in most osteosarcoma patients, but have no significant impact on response to chemotherapy or outcome in this large prospective series.OS 2006 trial registration number clinicaltrials.gov NCT00470223; date of registration: May 3th 2007.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3409-z) contains supplementary material, which is available to authorized users.

show abstract

Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

Cited by 24 publications

References 25 publications

High‐level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma

High‐level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma

Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

Contact Info

Product

Resources

About